physician photo

John E. Mazuski, MD, PhD

  • Professor of Surgery

Medical School

MD, University of California, Los Angeles, CA, 1981

Graduate School

PhD, Biochemistry, University of Minnesota, Minneapolis, MN, 1993

Post Doctoral Education

Surgery Resident, University of Minnesota Health Sciences Center, Minneapolis, MN, 1989

Chief Resident, Surgery, University of Minnesota Health Sciences Center, Minneapolis, MN, 1990

Surgical Critical Care Fellow, Department of Surgery, University of Minnesota Health Sciences Center, Minneapolis, MN, 1991

Board Certifications

Surgery--Certified
Surgical Critical Care--Certified

Clinical Interests

Dr. Mazuski specializes in burn, trauma and surgical critical care. Other areas of clinical interest include surgical infections; nutrition support; pathophysiology of shock, sepsis, and multiple organ failure; and clinical guidelines for surgical infections and for critically ill patients.

Research Interests

Governmental/Foundational
Principal Investigator: "Direct effects of endotoxin on hepatic acute phase protein synthesis," VA RAG Grant, 1992-1994

Principal Investigator: "Direct effects of endotoxin on hepatic acute phase protein synthesis," VA Merit Review Grant, 1994-1997

Consultant: "Detecting aspiration associated with tube feeding," NIH, 2002-2005

Local Investigator: "SIS multicenter study of duration of antibiotics for intra-abdominal infection," NIH, 2008-2009

Industry
Principal Investigator: Use of sedation in mechanically ventilated patients," Wyeth-Ayerst Laboratories, 1994-1995

Principal Investigator: "CP-116,517 and CP-99,219 versus imipenem/cilastatin and amoxicillin/clavulanic acid for treatment of serious intra-abdominal infections," Pfizer Central Research, 1995-1996

Principal Investigator: "CP-116,517 versus cefotetan for prophylaxis in elective colo-rectal surgery," Pfizer Central Research, 1995

Principal Investigator: "Alatrofloxacin/trovafloxacin versus ciprofloxacin and metronidazole for the treatment of serious intra-abdominal infections," Pfizer Inc., 1997-1999

Principal Investigator: "Recombinant platelet activating factor acetylhydrolase for ARDS," ICOS Corporation, 1999

Principal Investigator: "Direct effects of bacterial toxins in hepatocytes," St. Louis University School of Medicine Interim Research, 1999-2000

Principal Investigator: "Safety and efficacy of recombinant platelet-activating factor acetylhydrolase for reducing mortality in patients with severe sepsis," ICOS Corporation, 1999-2002

Principal Investigator: "Comparative study of daptomycin and linezolid in treatment of patients with suspected vancomycin-resistant infections," Cubist Pharmaceuticals, 2000-2002

Principal Investigator: "Prospective, randomized trial of moxifloxacin (intravenous, oral) versus intravenous piperacillin/tazobactam, oral amoxicillin/clavulanic acid for patients with complicated intra-abdominal infections," Bayer Corporation, 2001-2002

Principal Investigator: "Linezolid versus vancomycin for the treatment of patients with complicated skin and soft tissue infections," Pharmacia Corporation, 2001-2002

Principal Investigator: "Prospective, randomized trial of moxifloxacin (intravenous, oral) versus intravenous piperacillin/tazobactam, oral amoxicillin/clavulanic acid for patients with complicated intra-abdominal infections," Bayer Corporation, 2002-2003

Principal Investigator: "Meropenem versus imipenem/cilastatin for the treatment of patients with complicated skin/skin structure infections," Astra Zeneca Pharmaceuticals, LP, 2002-2003

Principal Investigator: "A comparison of omeprazole suspension to intravenous cimetidine for prevention of upper gastrointestinal bleeding due to stress-related mucosal damage," Santarus, Inc., 2002-2003

Principal Investigator: "Retrospective evaluation of EPO II trauma subpopulation to evauluate the association between measures of severity of illness and shock and the effects of epoetin alfa treatment on study outcomes," Ortho Biotech Products, LP, 2003

Principal Investigator: "Multicenter, double-blind, randomized study of the efficacy and safety of tigecycline compared to imipenem/cilastatin for the treatment of hospitalized patients with complicated intra-abdominal infectsions," Wyeth Research, 2003-2004

Principal Investigator: "Multicenter, double-blind, randomized study evaluating tigecycline and linezolid for the treatment of selected serious infections in subjects with vancomycin-resistant Enterococcus and evaluating tigecycline and vancomycine for the treatment of selected serious infections in subjects with methicllin-resistant Staphylococcus aureus," Wyeth Research, 2003-2005

Principal Investigator: "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of recombinant human erythropoietin (epoetin alfa) in critically ill subjects," Ortho Biotech, LLC, 2003-2006

Principal Investigator: "Randomized, double-blind, placebo-controlled trial of prophylactic heparin in pateints with severe sepsis and higher disease severity undergoing treatment with drotrecogin alfa (activated)," Eli Lilly and Company, 2004-2005

Principal Investigator: "A multicenter, double-blind, randomized, phase 3 study to compare the safety and efficacy of intravenous doripenem with that of meropenem in complicated intra-abdominal infections," Peninsula Pharmaceuticals, 2004-2006

Principal Investigator: "Linezolid for the treatment of subjects with nosocomial pmeumonia proven to be due to methicillin-resistant Staphylococcus aureus," Pfizer Inc., 2004-2010

Principal Investigator: "Intravenous telavancin versus vancomycin for treatment of complicated Gram-positive skin and skin structure infections, with a focus on patients with infections due to methicillin-resistant Staphylococcus aureus," Theravance, Inc., 2005-2006

Principal Investigator: "A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin (epoetin alfa) on functional outcomes in anemic, critically il, trauma subjects," Ortho Biotech, LLC, 2006-2008

Principal Investigator: "A prospective, multicenter observational registry involving patients hospitalized with complicated skin and soft tissue infections (cSSTI) for IV antibiotic therapy," Ortho Biotech, LLC, 2006-2008

Principal Investigator: "Efficacy and safety of drotrecogin alfa (activated) in adult patients with septic shock," Eli Lilly and Co., 2008-2010

International Coordinating Investigator: "A phase III, randomized, multi-center, double-blind, double-dummy, comparative study to dertermine the efficacy, safety, and tolerability of ceftazidime avibactam (CAZ104) plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections (cIAIs) in hospitalized adults," Astra Zeneca, 2011-2014

Current
Government - Principal Investigator: "SIS multicenter study of duration of antibiotics for intra-abdominal infections," NIH, 2010-PRESENT

Industry - Principal Investigator: "Protocol-based use of perioperative antibiotics for the prevention of infectious complications in patients undergoing laparotomy for abdominal trauma," Merck and Company, Inc., 2010-PRESENT

Industry - Principal Investigator: "A prospective, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of BAY 41-6551 as adjunctive therapy in intubated and mechanically ventilated patients with gram-negative pneumonia," Bayer, 2014-PRESENT

 

 

 

Hospital Affiliations

Barnes-Jewish Hospital

Patients Seen At

Surgical and Wound Care Clinic
Barnes Center for Outpatient Health
4901 Forest Park Ave.
Floor 3, Suite 340
St. Louis, MO 63108
314-362-5298
Fax: 314-362-5743

Contact Information

Washington University School of Medicine
Department of Surgery
Section of Burn/Trauma/Surgical Critical Care
Campus Box 8109, 660 S. Euclid Ave.
St. Louis, MO 63110
(314) 362-5307

Selected Publications

Durkin MJ, Dukes JL, Reeds DN, Mazuski JE, Camins BC. A descriptive study of the risk factors associated with catheter-related bloodstream infections in the home parenteral nutrition population. JPEN. 2015 Jan 16. [Epub ahead of print]

Eaton SR, Mazuski JE. Overview of severe Clostridium difficile infection. Crit Care Clin. 2013 Oct.;29(4): 827-839.

Skrupky LP, Tellor BR, Mazuski JE. Current strategies for the treatment of complicated intraabdominal infections. Expert Opin Pharmacother. 2013;14:1933-1947.

Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, Freire AX, Geehan D, Kohl B, Nasraway SA, Rigby M, Sands K, Schallom L, Taylor B, Umpierrez G, Mazuski J, Schunemann H:  Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012; 40:3251-3276.

Schwulst SJ, Mazuski JE: Surgical prophylaxis and complication avoidance care bundles. Surg Clin North America, 2012; 92:285-305.

Gnerlich JL, Ritter JH, Kirby JP, Mazuski JE: Simultaneous necrotizing soft tissue infection and colonic necrosis due to Clostridium septicum. Surg Infect. 2010; 12:501-506.

Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt). 2010 Feb;11(1):79-109.

Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010 Jan 15;50(2):133-64.

Byrnes MC, Schuerer DJ, Schallom ME, Sona CS, Mazuski JE, Taylor BE, McKenzie W, Thomas JM, Emerson JS, Nemeth JL, Bailey RA, Boyle WA, Buchman TG, Coopersmith CM. Implementation of a mandatory checklist of protocols and objectives improves compliance with a wide range of evidence-based intensive care unit practices. Crit Care Med. 2009 Oct;37(10):2775-81.

Efron PA, Mazuski JE. Clostridium difficile colitis. Surg Clin North Am. 2009 Apr;89(2):483-500, x.

Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am. 2009 Apr;89(2):421-37, ix. Review.

Kirby JP, Mazuski JE. Prevention of surgical site infection. Surg Clin North Am. 2009 Apr;89(2):365-89, viii. Review.

Mazuski JE. Preface. Surg Clin North Am. 2009 Apr;89(2):xvii-xix.

Byrnes MC, Mazuski JE. Antimicrobial therapy for acute colonic diverticulitis. Surg Infect (Larchmt). 2009 Apr;10(2):143-54. Review.

Mazuski JE. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt). 2008 Dec;9(6):567-71.

Sona CS, Zack JE, Schallom ME, McSweeney M, McMullen K, Thomas J, Coopersmith CM, Boyle WA, Buchman TG, Mazuski JE, Schuerer DJ. The impact of a simple, low-cost oral care protocol on ventilator-associated pneumonia rates in a surgical intensive care unit. J Intensive Care Med. 2009 Jan-Feb;24(1):54-62.

Pub Med page for John E. Mazuski, MD, PhD

Books

Mazuski JE, guest editor. Surgical Infections: Surgical Clinics of North America, 2009: Volume 89, Number 2.

Editorial Positions

Journal Editor

2008-Present, Editorial Board, Surgical Infections

Journal Reviewer

2001-Present, Intensive Care Medicine
2001-Present, Surgical Infections
2005-Present, Journal of the American College of Surgery
2007-Present, Expert Opinion on Investigational Drugs
2008-Present, Drugs
2009-Present, American College of Critical Care
2009-Present, Lancet Infectious Diseases
2012-Present, Journal of Parenteral and Enteral Nutrition

Chapters

Mazuski JE:  Intra-abdominal infections. In: Fry D, ed. Surgical Infections. JP Medical Publishers, London, 2013; pp. 75-88.

Husain, KD, Mazuski JE, Hotchkiss, R: Life support and anesthesia. In: Klingensmith ME, Chen LE, Glasgow SC, Goers TA, Melby SJ, eds. The Washington Manual of Surgery, Washington University School of Medicine, 5th Edition, Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2008:46-70.

Taylor B, Mazuski J: Enteral access devices in the critically ill patient. In: Cresci G, ed. Nutrition Support for the Critically Ill Patient: A Guide to Practice. Boca Raton: Taylor and Francis Group; 2005:235-252.

Bailey JA, Mazuski JE: Divalent ions in the ICU. In: Abrams JH, Druck P, Cerra FB, eds. Surgical Critical Care, 2nd Edition. Boca Raton: Taylor and Francis Group; 2005:647-660.

Mazuski JE, Sawyer, R, Nathens A, DiPiro J, Schein M, Kudsk KA, Yowler C: Antibiotics as an adjunct to source control:  Revised Surgical Infection Society guidelines for antimicrobial therapy of intra-abdominal infections. In: Marshall J, Schein M, eds. Source Control. Berlin Heidelberg: Springer-Verlag; 2003:427-441.